Your AI-Trained Oncology Knowledge Connection!
Michael Bishop, MD, is a professor of medicine and director of the Hematopoietic Stem Cell Transplantation Program at University of Chicago Medicine.
Dr Michael Bishop, of the David and Etta Jonas Center for Cellular Therapy, University of Chicago, describes the rationale for the design of the phase 3 REACH2 trial in steroid-refractory acute graft-versus-host disease and provides perspective on important takeaways from data presented.
Considerations for assessing response to steroid therapy as initial therapy for acute graft-versus-host disease and factors that impact next-line therapy, when necessary.
Michael Bishop, MD, shares recommendations that can help hematologists/oncologists appropriately identify patients with steroid-refractory acute graft-versus-host disease and describes how his treatment approaches differ based on grade.
Criteria used by hematologists/oncologists to diagnose acute graft-versus-host disease (GVHD), and common therapies used for GVHD prevention in patients who receive hematopoietic stem cell transplantation.
Michael Bishop, MD, discusses his concerns for a 53-year-old man diagnosed with acute graft-versus-host disease later deemed as steroid refractory, based on the typical prognosis for patients in similar scenarios.
Recommendations for using ruxolitinib to treat a 53-year-old patient with acute graft-versus-host disease whose disease progresses following previous treatment with steroid therapy.
